Andreas Seidl

Andreas is COO of Leukocare, heading R&D, IP, quality management and Bioinformatics. Andreas has about 20 years experience in analytical and pharmaceutical development of biologics and contributed to the development and approval of many biosimilar products and NBEs. Before joining Leukocare, Andreas held different positions with growing responsibility at Hexal AG, Sandoz Biopharmaceuticals and Novartis. Andreas is a chemist by training with a master’s degree from the University of Constance/Germany and received his Ph.D. in the area of protein analysis and mass spectrometry from the University of Constance.